Aptabio Obtains Patent Related to Blood Cancer Treatment
[Asia Economy Reporter Minwoo Lee] Aptabio announced on the 2nd that it obtained a patent for a "blood cancer treatment drug" on the 1st in collaboration with Samjin Pharmaceutical.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "If Both Spouses Work There, How Much Would They Make?" "They Earn More Than Me, and I'm a Doctor"... Envy Erupts Over Samsung Electronics' Bonus
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Aptabio stated, "The novel aptamer-drug conjugate of this patented technology is a new structure of oligonucleotide modified nucleic acid containing one or more therapeutic modified nucleic acids. It has a cell death effect on blood cancer cells and drug-resistant blood cancer cells and possesses blood cancer treatment efficacy." They added, "A composition containing this as an active ingredient can be developed for the prevention, improvement, or treatment of blood cancer."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
